EVIDENCE - 1977 TO 2024
DSIP Research: The Forty-Year Record, Findings and Gaps
The slow-wave sleep result that named it, the saturable brain transport, the neuroendocrine and longevity data, and the receptor that has never been found.
Start here
DSIP research goes back to 1977 and covers a lot of ground: deep sleep, how the molecule gets into the brain, stress hormones, growth hormone, and even animal lifespan. The headline finding is simple, that infusing DSIP into the brain boosts the slow, deep brain waves of deep sleep. The complication is that the most basic question, what exactly DSIP latches onto in the body, has never been answered, and the human sleep evidence is small and mixed. Below, each major finding gets its own heading, written plainly, with the species, the route, and the dose stated for every study and a numbered source for every number. The studies are real; the gaps are real too, and both are kept in plain sight rather than smoothed over.
DSIP for sleep: the founding finding
The result that started everything: in 1977, DSIP was isolated and characterized as a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) that, infused intraventricularly (directly into the brain's fluid-filled chambers), produced a significant and specific enhancement of delta and spindle EEG patterns, the brain-wave signatures of deep sleep [1]. The effect crosses species and routes, too: subcutaneous DSIP at 120 nmol/kg in cats significantly increased slow-wave sleep without suppressing REM and reduced waking, which matters because it shows a peptide given outside the brain can still reach the central nervous system and act [7].
The human picture is where DSIP for sleep gets honest. Acute intravenous DSIP at 25 nmol/kg in six middle-aged chronic insomniacs improved disturbed sleep, longer duration, fewer interruptions, slightly more REM, no daytime sedation, with the benefit emerging in the second hour after injection [2]. A double-blind study at the same 25 nmol/kg dose found higher sleep efficiency and shorter sleep latency than placebo, but the authors characterized the effect as modest and concluded short-term treatment alone was unlikely to be of major therapeutic benefit [18]. Real, repeatable in a small way, and clinically modest, all at once.
Crossing the blood-brain barrier
For a peptide given outside the brain to affect sleep, it has to get in. DSIP does, and by a specific mechanism. In the vascularly perfused guinea-pig brain, DSIP crossed the blood-brain barrier through a saturable, high-affinity transport system, competitively inhibited by L-tryptophan, indicating specific binding sites on the capillary membrane rather than passive leakage [8]. A complementary dog study found that a three-factor model combining plasma level, half-life, and lipophilicity (fat-solubility) predicted how well DSIP analogs entered the cerebrospinal fluid, giving a rational basis for designing better brain-targeting versions [9]. This blood-brain-barrier transport work is the lens this site is built around; the dedicated DSIP half life page follows it in full, and the broader idea that peptides cross the barrier in both directions through dynamic, saturable carriers is laid out in a 2015 review [14].
Beyond sleep: stress hormones, growth hormone, and reproduction
DSIP's reported reach goes past sleep, which is part of why its biology is hard to pin down. In men, intravenous DSIP at 25 nmol/kg produced a significant reduction in plasma ACTH-like immunoreactivity for at least three hours while cortisol stayed on its normal daily decline, hinting at a selective touch on the stress axis [4]. In rats, DSIP stimulated the release of luteinizing hormone (LH) but not FSH through a hypothalamic site, with LH staying elevated for about two hours, suggesting a reproductive-neuroendocrine role [20].
The catch is cross-species non-replication. Rat work points to DSIP raising growth hormone via a dopamine pathway, but human studies in women found no growth-hormone or prolactin effect, and the early human ACTH result above was not reproduced in a later human study. A molecule that does several different things in several different species, none of them reliably reproduced across the species line, is exactly the kind that resists a single clean mechanism.
Antioxidant, mitochondrial, and longevity studies
A separate research strand, largely from Russian groups, studied DSIP as a stress-protective and anti-aging agent. Monthly five-day courses of the DSIP-containing preparation Deltaran (~100 micrograms/kg) in female SHR mice increased maximum lifespan by 24.1%, extended the last 10% of survivors' lifespan by 17.1%, cut total spontaneous tumor incidence 2.6-fold, and reduced bone-marrow chromosome aberrations by 22.6% [5]. In aging rats, subcutaneous DSIP increased expression of the antioxidant enzyme genes SOD1 and Gpx1 in brain and blood, expression that otherwise declines with age [13], and stabilized mitochondrial NADH-dehydrogenase activity while leaving succinate dehydrogenase unchanged [15]. These are striking numbers, but they come from a small set of related groups using one preparation and need independent replication before any strong claim, a caveat the appraisal keeps attached.
Pharmacology, analogs, and the missing receptor
Two things shape how DSIP behaves. It is cleared fast: an enzyme-immunoassay study reported plasma half-lives on the order of only a few minutes in dogs, monkeys, and rats, consistent with rapid enzymatic breakdown [10]; in rat brain homogenate, degradation released its N-terminal tryptophan with a defined pH optimum [11]. And its activity is structurally fussy: a characterization review described a parabolic (non-monotonic) dose-response, endogenous distribution in plasma, CSF, and milk bound to a carrier protein, and a phosphorylated analog (DSIP-P) more potent than the parent [17]. Tellingly, a related peptide, KND, showed antioxidative, anticonvulsive, and behavioral effects even more pronounced than DSIP's, prompting the idea that KND may be an endogenous prototype [12].
Underneath all of it sits the riddle. No DSIP receptor, gene, or precursor has ever been conclusively isolated; the 2006 Journal of Neurochemistry review called the sleep evidence 'extremely poorly documented and still weak' and noted that synthetic analogs, not native DSIP, drove the clearest effects [3]. Modern interest is real but peripheral, DSIP still appears in recent peptide reviews, including a 2026 orthopaedics survey of recovery-enhancing agents [21], even as the central mechanistic question stays open. A 2024 study did show that a DSIP fusion peptide engineered to cross the blood-brain barrier (DSIP-CBBBP) cut wakefulness by about 31% in a chemically induced insomnia mouse model and outperformed unmodified DSIP, hinting that delivery and stability, not the core idea, may be the limiting factors [6].